PCNII COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCERWITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65745-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)65745-2/fulltext
Title :
PCNII COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCERWITH BONE METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65745-2&doi=10.1016/S1098-3015(10)65745-2
First page :
Section Title :
Open access? :
No
Section Order :
113